SEC FORM 3

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Or Yat Sun

(Last)

(First)

(Middle)

C/O ENANTA PHARMACEUTICALS, INC.

500 ARSENAL STREET

(Street)

WATERTOWN

02472

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
03/20/2013

3. Issuer Name and Ticker or Trading Symbol
ENANTA PHARMACEUTICALS INC [ ENTA ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Scientific Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	79,991	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (right to buy)	⁽¹⁾	07/01/2014	Common Stock	121,837	$0.73	D
Stock Option (right to buy)	⁽¹⁾	12/23/2014	Common Stock	7,250	$0.73	D
Stock Option (right to buy)	⁽¹⁾	06/23/2016	Common Stock	11,149	$1.29	D
Stock Option (right to buy)	⁽¹⁾	07/12/2017	Common Stock	50,723	$2.97	D
Stock Option (right to buy)	⁽¹⁾	07/11/2018	Common Stock	13,921	$1.98	D
Stock Option (right to buy)	⁽¹⁾	03/05/2019	Common Stock	13,921	$1.51	D
Stock Option (right to buy)	⁽¹⁾	05/25/2020	Common Stock	6,960	$1.21	D
Stock Option (right to buy)	⁽²⁾	06/18/2020	Common Stock	51,044	$1.21	D
Stock Option (right to buy)	⁽¹⁾	04/15/2021	Common Stock	13,921	$2.54	D
Stock Option (right to buy)	⁽³⁾	06/17/2021	Common Stock	5,800	$2.54	D
Stock Option (right to buy)	⁽⁴⁾	09/23/2021	Common Stock	23,201	$2.54	D
Stock Option (right to buy)	⁽¹⁾	06/20/2022	Common Stock	13,921	$11.77	D
Stock Option (right to buy)	⁽⁵⁾	06/20/2022	Common Stock	4,872	$11.77	D
Stock Option (right to buy)	⁽⁶⁾	12/26/2022	Common Stock	13,921	$14.18	D

Explanation of Responses:

1. 100% of the shares subject to the option are fully vested and exercisable.

2. 50% of the shares subject to the option became fully vested and exercisable as of June 18, 2010 (the "Grant Date"), and the remaining shares vest in thirty-six (36) successive and equal monthly installments thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Grant Date.

3. 50% of the shares subject to the option became fully vested and exercisable as of June 17, 2011 (the "Grant Date"), and the remaining shares vest in thirty-six (36) successive and equal monthly installments thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Grant Date.

4. 50% of the shares subject to the option became fully vested and exercisable as of September 23, 2011 (the "Grant Date"), and the remaining shares vest in thirty-six (36) successive and equal monthly installments thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Grant Date.

5. 50% of the shares subject to the option became fully vested and exercisable as of June 20, 2012 (the "Grant Date"), and the remaining shares vest in thirty-six (36) successive and equal monthly installments thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Grant Date.

6. The shares subject to the option will become fully exercisable on December 31, 2013.

Remarks:

	/s/ Yat Sun Or	03/20/2013
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.